Home >> Marketplace Archives >> Study: Kadcyla improved invasive disease-free survival

Study: Kadcyla improved invasive disease-free survival

Print Friendly, PDF & Email

November 2018—Roche announced the phase three KATHERINE study met its primary endpoint, showing Kadcyla (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival) compared with trastuzumab as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. The safety profile of Kadcyla in the KATHERINE study was consistent with previous clinical trials and no new safety signals were identified.

Roche, 317-521-2000

x

Check Also

Roche announces availability of FoundationOne Liquid

Sept. 27, 2018—Roche announced that its FoundationOne Liquid, a blood-based genomic profiling test, is available worldwide. FoundationOne Liquid can identify circulating tumor DNA in the blood of people with cancer and can identify 70 of the most commonly mutated genes in solid tumors, including microsatellite instability.

X